Skip to main content
OpenTrials
Completed

NCT Number: NCT00112437

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

This is a 1-year base study with a 1-year extension to examine the effects of a new experimental medication (odanacatib [MK-0822]) on postmenopausal osteoporosis. This study will enroll approximately 375 postmenopausal women, and randomly assign them to 4 different doses of odanacatib or to placebo. Measurements performed during the study include: bone mineral density scans, spine x-rays, laboratory blood and urine tests, height measurements and optional bone biopsies (at the end of 2 years).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoporosis Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases

Age range

45 year–85 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

About this study

Study Extension:

Participants who completed 12 months of the base study and 12 months of the first extension were invited to continue in three additional extensions: MK0-822-004-10, which extended the study to 36 months, MK-0822-004-20 (NCT00112437) which extended the study to 60 months, and MK-0822-004-30 (NCT00112437), which extended the study to 120 months.

  • In the first extension, participants continued to receive the same treatment they received in the 12-month base study.
  • In the second extension, participants were re-randomized to odanacatib 50 mg OW or placebo OW for 12 months.
  • In the third extension, participants who were initially randomized to odanacatib 3 mg or placebo OW in the base study received odanacatib 50 mg weekly in Years 4 and 5; all other participants remained on the same treatment they were during Year 3.
  • In the fourth extension, all participants received odanacatib weekly in Years 6-10.

Study arms for extensions include only odanacatib 50 mg and placebo for the first two extensions and odanacatib 50 mg only for the third extension.

Extension Studies:

MK-0822-004-10 (NCT00112437) Extension: Participant has participated in and completed 24 months of treatment in the base study

MK-0822-004-20 (NCT00112437) Extension: Participant participated in and completed 36 months of treatment in base and extension studies.

MK-0822-004-30 (NCT00112437) Extension: Participant participated in and completed 60 months of treatment in the base and extension studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Postmenopausal for 5 or more years, defined as no menses for at least 5 years OR at least 5 years status post bilateral oophorectomy
  • Bone mineral density T-score at the hip or spine of -2.0 or less
  • Spinal anatomy suitable for dual-energy x-ray absorptiometry (DXA). At the lumbar spine, there is no evidence of vertebral fracture in at least 3 vertebrae in the L1 to L4 region on baseline spine films. (Significant scoliosis, bony trauma, degenerative joint disease, and sequelae of orthopedic procedures that result in anatomy that is unsuitable for accurate bone densitometry must be absent from the lumbar spine.)
  • At least one hip must be evaluable by DXA (e.g., contain no hardware from orthopedic procedures)
  • In a state of general health allowing for successful completion of the trial
  • Agreement to not use any medications to treat osteoporosis during the study

Exclusion criteria

  • History of prior osteoporotic fracture (unless declined treatment with or was ineligible for osteoporosis therapy)
  • Past treatment with osteoporosis medications, steroids, hormone replacement, as well as various other medications that affect bone may be exclusionary. (Different exclusion criteria apply to each bone active drug. For example, any prior use of intravenous (IV) bisphosphonates is not permitted. By contrast, prior use of hormone replacement for several years is permitted if it has not occurred within the past 6 months. Please ask the study doctor for details)
  • Significant clinical or laboratory abnormalities at the screening visit for the study that, in the opinion of the investigator, could complicate interpretation of the study results or pose additional risk to the patient (for example, patients who are non-ambulatory should be excluded for this reason)

Treatment and study plan

odanacatib

Drug

Odanacatib 3 mg, once weekly for 24 months

Other names: MK-0822

Vitamin D3

Dietary Supplement

Vitamin D3, two 2800 IU weekly throughout the study

Calcium Carbonate

Dietary Supplement

Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.

Placebo

Drug

Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months

Primary outcomes

  1. Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months

    Time frame: Baseline and 12 months

    Percentage change in lumbar spine BMD (relative to baseline) at 12 Months.

  2. Percentage Change From Baseline in Lumbar Spine BMD at 24 Months

    Time frame: Baseline and 24 months

    Percentage change in lumbar spine BMD (relative to baseline) at 24 Months.

  3. Percentage Change From Baseline in Lumbar Spine BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change in lumbar spine BMD (relative to baseline) at 36 months

  4. Percentage Change From Baseline in Lumbar Spine BMD at 60 Months

    Time frame: Baseline and Month 60

    Percentage change from baseline in lumbar spine BMD at 60 months.

  5. Percentage Change From Baseline in Lumbar Spine BMD at 120 Months

    Time frame: Baseline and Month 120

    Percentage change from baseline in lumbar spine BMD at 120 Months.

  6. Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment Years 6-10 (60 Months)

    Time frame: Years 6-10 (up to 60 months, up to 14 days after the last dose of study drug)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

  7. Number of Participants Who Discontinued Study Drug Due to an AE During Treatment Years 6-10 (60 Months)

    Time frame: Years 6-10 (up to 60 months)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

Secondary outcomes

  1. Percentage Change From Baseline in Total Hip BMD at 12 Months

    Time frame: Baseline and 12 months

    Percentage change in total hip BMD (relative to baseline) at 12 months

  2. Percentage Change From Baseline in Femoral Neck BMD at 12 Months

    Time frame: Baseline and 12 months

    Percentage change in femoral neck BMD (relative to baseline) at 12 months

  3. Percentage Change From Baseline in Trochanter BMD at 12 Months

    Time frame: Baseline and 12 Months

    Percentage change in trochanter BMD (relative to baseline) at 12 months

  4. Percentage Change From Baseline in Total Body BMD at 12 Months

    Time frame: Baseline and 12 Months

    Percentage change in total body BMD (relative to baseline) at 12 months

  5. Percentage Change From Baseline in Distal Forearm BMD at 12 Months

    Time frame: Baseline and 12 Months

    Percentage change in distal forearm BMD (relative to baseline) at 12 months

  6. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary N-Telopeptides of Type I Collagen [u-NTx]) at 12 Months

    Time frame: Baseline and 12 Months

    Back-transformation (geometric mean) of the Least Squares (LS) Mean of the log-values Percentage change from baseline, in Biochemical Marker of Bone turnover (urinary N-telopeptides of Type I collagen (u-NTx)) at 12 Months

  7. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum C-Telopeptides of Type 1 Collagen [s-CTx]) at 12 Months

    Time frame: Baseline and 12 Months

    Back-transformation (geometric mean) of the Least Squares (LS) Mean of the log-values Percentage change from baseline in Biochemical Marker of Bone turnover (serum C-telopeptides of Type 1 collagen (s-CTx)) at 12 Months.

  8. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary Total Deoxypyridinolines [u-DPyr]) at 12 Months

    Time frame: Baseline and 12 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values percentage change from baseline in biochemical marker of bone turnover (urinary total deoxypyridinolines (u-DPyr)) (relative to baseline) at 12 Months

  9. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum Bone-specific Alkaline Phosphatase [s-BSAP]) at 12 Months

    Time frame: Baseline and 12 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values Percentage change from baseline, in Biochemical Marker of Bone turnover (serum bone-specific alkaline phosphatase (s-BSAP)), at 12 Months

  10. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum N-Terminal Propeptide of Type 1 Collagen [s-P1NP]) at 12 Months

    Time frame: Baseline and 12 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values Percentage change in Biochemical Marker of Bone turnover (serum N-terminal propeptide of Type 1 collagen (s-P1NP) (relative to baseline) at 12 Months

  11. Percentage Change From Baseline in Total Hip Bone Mineral Density at 24 Months

    Time frame: Baseline and 24 months

    Percentage change in total hip Bone Mineral Density (relative to baseline) at 24 Months

  12. Percentage Change From Baseline in Femoral Neck BMD at 24 Months

    Time frame: Baseline and 24 months

    Percentage change in femoral neck Bone Mineral Density (relative to baseline) at 24 Months

  13. Percentage Change From Baseline in Trochanter BMD at 24 Months

    Time frame: Baseline and 24 months

    Percentage change from baseline in trochanter BMD (relative to baseline) at 24 Months

  14. Percentage Change From Baseline in Total Body BMD at 24 Months

    Time frame: Baseline and 24 months

    Percentage change in total body BMD (relative to baseline) at 24 Months

  15. Percentage Change From Baseline in Distal Forearm BMD at 24 Months

    Time frame: Baseline and 24 months

    Percentage change in distal forearm BMD (relative to baseline) at 24 Months

  16. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary N-Telopeptides of Type I Collagen [u-NTx]) at 24 Months

    Time frame: Baseline and 24 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values percentage change from baseline in biochemical marker of bone turnover (u-NTx) (relative to baseline) at 24 Months

  17. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum C-Telopeptides of Type 1 Collagen [s-CTx]) at 24 Months

    Time frame: Baseline and 24 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values Percentage change from baseline, in Biochemical Marker of Bone turnover (serum C-telopeptides of Type 1 collagen (s-CTx)) (relative to baseline) at 24 Months

  18. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary Total Deoxypyridinolines [u-DPyr]) at 24 Months

    Time frame: Baseline and 24 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values Percentage change from baseline, in Biochemical Marker of Bone turnover (urinary total deoxypyridinolines (u-DPyr)) (relative to baseline) at 24 Months

  19. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum Bone-specific Alkaline Phosphatase [s-BSAP]) at 24 Months

    Time frame: Baseline and 24 months

    Back-transformation (geometric mean) of the Least Squares Mean of the log-values Percentage change from baseline, in Biochemical Marker of Bone turnover (serum bone-specific alkaline phosphatase (s-BSAP)) (relative to baseline) at 24 Months

  20. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum N-Terminal Propeptide of Type 1 Collagen [s-P1NP]) at 24 Months

    Time frame: Baseline and 24 months

    Back-transformation (geometric mean) of the least squares mean of the log-values percentage change from baseline in biochemical marker of bone turnover (s-P1NP) (relative to baseline) at 24 months

  21. Percentage Change From Baseline in Total Hip BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change in total hip BMD (relative to baseline) at 36 months

  22. Percentage Change From Baseline in Femoral Neck BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change in femoral neck BMD (relative to baseline) at 36 Months

  23. Percentage Change From Baseline in Trochanter BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change in trochanter BMD (relative to baseline) at 36 months

  24. Percentage Change From Baseline in Total Body BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in total body BMD (relative to baseline) at 36 Months

  25. Percentage Change From Baseline in Distal Forearm BMD at 36 Months

    Time frame: Baseline and 36 months

    Percentage change in distal forearm BMD (relative to baseline) at 36 Months

  26. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary N-Telopeptides of Type I Collagen [u-NTx]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover (u-NTx) at 36 Months

  27. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum C-Telopeptides of Type 1 Collagen [s-CTx]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover (s-CTx) at 36 Months

  28. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Urinary Total Deoxypyridinolines [u-DPyr]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover u-DPyr at 36 Months

  29. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum Bone-specific Alkaline Phosphatase [s-BSAP]) at 36 Months

    Time frame: Baseline and 36 months

    Geometric Mean Percentage change from baseline, in Biochemical Marker of Bone turnover (serum bone-specific alkaline phosphatase [s-BSAP]) at 36 Months

  30. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum N-terminal Propeptide of Type 1 Collagen [s-P1NP]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover (serum N-terminal propeptide of Type 1 collagen [s-P1NP]) at 36 months

  31. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum Bone Tartrate-resistant Acid Phosphatase Isoform 5b [TRAP 5-b]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover (serum bone tartrate-resistant acid phosphatase isoform 5b [TRAP 5-b]) at 36 Months

  32. Percentage Change From Baseline in Biochemical Marker of Bone Turnover (Serum Cross-Linked Carboxyterminal Telopeptides of Type I Collagen [1-CTP]) at 36 Months

    Time frame: Baseline and 36 months

    Percentage change from baseline in biochemical marker of bone turnover (serum Cross-Linked Carboxyterminal Telopeptides of Type I Collagen [1-CTP]) at 36 Months

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women With Osteoporosis

Important dates

Study start
2005
Primary completion
2007
Study completion
2016
First posted
Jun 3, 2005
Registry last updated
Jan 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.